The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.

A revolutionary breakthrough in cataract treatment is on the horizon, with the emergence of C-KAD, a new eye drop therapy.

Shares of Cybin, Inc. ($CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the ...

The average CEO reads 4-5 books per month, while most Americans finish just one book per year. Here are this week's top new ...

Researchers at Northwestern Medicine Canning Thoracic Institute have uncovered a startling connection between COVID-19 ...

Experts have discovered that salmonella has been depleting a key protein which the body’s own immune cells need to function.

ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, delivered via a proprietary controlled- release carrier intended to resolve metastatic breast cancer bone lesions, inhibit pain while ...

The birth of your baby is supposed to be one of the most joyous moments of a new mom’s life, but for one in seven new mothers ...

CHICAGO -- Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

Canadians will get child benefit cheques this week amid Canada Post strike Canadians will get child benefit cheques this week amid Canada Post strike Parents who are expecting child benefit ...